Denmark, 31 October 2014 – Novo Nordisk today announced an investment of approximately 750 million Danish kroner (around 130 million US dollars) in new laboratories at the company’s R&D campus in Måløv, Denmark. Construction has started, and the new laboratory facility is expected to be ready for occupation in early 2016.
The new facility – Diabetes Research House – will accommodate approximately 350 employees. During the construction phase, the project is expected to generate more than 1,000 jobs outside Novo Nordisk.
«The new lab facility will provide an environment for cutting-edge diabetes research within biotechnology and protein chemistry,» said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. «Here our researchers will be working closely together with leading scientists in Denmark and abroad on the discovery and development of new medicines for the treatment of type 1 and type 2 diabetes.»
The facility comprises two laboratory wings, a middle building with office space and an auditorium seating 450 people. The facility will have a floorage of 16,500 square metres distributed on three storeys.
Novo Nordisk opened its R&D campus in Måløv in 1991 with about 300 employees. Today the campus accommodates more than 2,300 employees. Globally, about 5,000 employees are involved in research and development activities at Novo Nordisk’s R&D units in Denmark, the US and China.
Graphics of Diabetes Research House can be downloaded on novonordisk.com under Photos.
Read the full release
Novo Nordisk is a focused healthcare company.
Novo Nordisk is a healthcare company and a world leader in diabetes care.
In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society.